< a ALT = "697" id = "sign" > < / a > recently, the New England Journal of Medicine published online the results of the international multicenter randomized, double-blind, placebo-controlled phase III clinical trial of the recombinant protein subunit newcrown vaccine zf2001 jointly developed by the Gaofu academician team of the Institute of Microbiology of the Chinese Academy of Sciences and Zhifei Biology (300122).
The results showed that zf2001 could effectively prevent COVID-19 of different severity and was safe and well tolerated.
In the long-term effectiveness analysis (as of December 15, 2021) after completing the whole course of vaccination for about 6 months, the protective efficacy of the vaccine against COVID-19 of different severity can still reach 75.7%, and the protective efficacy against severe and critical COVID-19 can reach 87.6%; The protective effect on death caused by COVID-19 was 86.5%.
The protection rate of delta mutant was still as high as 76.1%, while that of alpha mutant was 88.3%; It is suggested that the vaccine still has high protective effect half a year after the whole process of vaccination.
6123805